Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

29.57USD
4:00pm EDT
Change (% chg)

$0.05 (+0.17%)
Prev Close
$29.52
Open
$29.52
Day's High
$29.60
Day's Low
$29.37
Volume
614,349
Avg. Vol
1,425,547
52-wk High
$29.60
52-wk Low
$19.67

Chart for

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $40,505.19
Shares Outstanding(Mil.): 1,372.13
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 164.04 17.08
EPS (TTM): -- -- --
ROI: -- 9.56 11.26
ROE: -- 14.93 15.09

BRIEF-Boston Scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary

* Boston scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Boston Scientific to buy Apama Medical

* Boston Scientific announces agreement to acquire Apama Medical

Oct 02 2017

Panel refuses to revive $200 mln stent case against Boston Scientific

A federal appeals court on Friday refused to revive a $200 million patent lawsuit filed by a cardiologist against Boston Scientific Corp over coronary stents, saying a lower court judge was right to throw out a jury verdict for the doctor.

Sep 29 2017

BRIEF-Boston Scientific announces positive late-breaking clinical trial data for Heartlogic Heart Failure Diagnostic

* Boston Scientific announces positive late-breaking clinical trial data for the Heartlogic Heart Failure Diagnostic Source text for Eikon: Further company coverage:

Sep 19 2017

BRIEF-Veniti Inc announces Boston Scientific distribution agreement for VICI VENOUS STENT

* ‍Veniti Inc -Boston Scientific will distribute VICI VENOUS STENT under limited global distribution agreement; terms of agreement, specific regions, countries involved were not disclosed​ Source text for Eikon:

Sep 11 2017

Judge dismisses Boston Scientific whistleblower complaint

A federal judge has dismissed a whistleblower lawsuit claiming Boston Scientific Corp caused doctors to make false claims for reimbursement from federal healthcare programs for two defective defibrillator products.

Aug 31 2017

BRIEF-Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing

* Boston Scientific Corp - on August 4, 2017, Boston Scientific Corporation entered into a $2.25 billion senior unsecured credit facility

Aug 07 2017

Boston Scientific beats profit estimates, raises forecast

Boston Scientific Corp on Thursday reported better-than-expected quarterly profit and revenue as the U.S. medical device maker benefited from strong demand across its businesses, which also helped the company raise full-year expectations.

Jul 27 2017

UPDATE 2-Boston Scientific beats profit estimates, raises forecast

July 27 Boston Scientific Corp on Thursday reported better-than-expected quarterly profit and revenue as the U.S. medical device maker benefited from strong demand across its businesses, which also helped the company raise full-year expectations.

Jul 27 2017

Boston Scientific posts profit in second quarter

July 27 Medical device maker Boston Scientific Corp on Thursday posted a profit in the second quarter compared with a year-ago loss, helped by higher sales as well as lower litigation-related expenses.

Jul 27 2017

Competitors

Earnings vs. Estimates